Literature DB >> 7107705

Coupling of proadipocyte growth arrest and differentiation. I. Induction by heparinized medium containing human plasma.

B R Krawisz, R E Scott.   

Abstract

The differentiation of proadipocytes in vitro typically required prolonged culture of cells as a high density in high concentrations of serum and added hormones. With such culture conditions it is difficult to design experiments to determine the mechanisms that control the differentiation process. We now describe the rapid and parasynchronous growth arrest and differentiation of low density murine proadipocytes in heparinized medium containing only human plasma. When low density cells are cultured under these conditions, growth arrest at a distinct state in the G1 phase of the cell cycle occurs within 2 d and the differentiation of 80-100% of the cell population occurs within 4 d thereafter. The factors in human plasma which promote growth arrest and differentiation are heat labile and can be separated by barium adsorption. In the following paper we have used these methods to show that there are five separate phases which regulate the coupling of proadipocyte growth arrest and differentiation. The data reported in this paper establish that: (a) high cell density and extensive cell-to-cell contact are not required for adipocyte differentiation, (b) prolonged culture is not required for adipocyte differentiation, and (c) high concentrations of serum and/or added hormones are not required for adipocyte differentiation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107705      PMCID: PMC2112890          DOI: 10.1083/jcb.94.2.394

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  21 in total

1.  Prothrombin.

Authors:  K G Mann
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

2.  An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion.

Authors:  H Green; O Kehinde
Journal:  Cell       Date:  1975-05       Impact factor: 41.582

3.  Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis.

Authors:  B Astedt; W Mattsson; C Tropé
Journal:  Acta Med Scand       Date:  1977

4.  Nuclear RNA polymerase activities and poly(A)-containing mRNA accumulation in cultured AKR mouse embryo cells stimulated to proliferate.

Authors:  E W Benz; M J Getz; D J Wells; H L Moses
Journal:  Exp Cell Res       Date:  1977-08       Impact factor: 3.905

Review 5.  The effect of heparin and warfarin on primary and metastatic tumors.

Authors:  R C Millar; A S Ketcham
Journal:  J Med       Date:  1974

6.  An established pre-adipose cell line and its differentiation in culture.

Authors:  H Green; M Meuth
Journal:  Cell       Date:  1974-10       Impact factor: 41.582

7.  Isoleucine-mediated regulation of genome repliction in various mammalian cell lines.

Authors:  R A Tobey; K D Ley
Journal:  Cancer Res       Date:  1971-01       Impact factor: 12.701

8.  Distribution of intravenously induced metastases in heparin- and coumarin-treated mice.

Authors:  B Hagmar; B Boeryd
Journal:  Pathol Eur       Date:  1969

9.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

Authors:  T R Chen
Journal:  Exp Cell Res       Date:  1977-02       Impact factor: 3.905

10.  Heparin and chemotherapy in the management of inoperable lung carcinoma.

Authors:  E G Elias; S K Shukla; I B Mink
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

View more
  17 in total

1.  Metaplastic change in mesenchymal stem cells induced by activated ras oncogene.

Authors:  C Y Tzen; M Filipak; R E Scott
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

2.  Partial characterization of a cellular factor that regulates the double-stranded RNA-dependent eIF-2 alpha kinase in 3T3-F442A fibroblasts.

Authors:  R Judware; R Petryshyn
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

3.  The proliferation potential protein-related (P2P-R) gene with domains encoding heterogeneous nuclear ribonucleoprotein association and Rb1 binding shows repressed expression during terminal differentiation.

Authors:  M M Witte; R E Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Nonterminal differentiation represses the neoplastic phenotype in spontaneously and simian virus 40-transformed cells.

Authors:  R E Scott; D N Estervig; C Y Tzen; P Minoo; P B Maercklein; B J Hoerl
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

5.  Biologic mechanisms for the regulation of normal human keratinocyte proliferation and differentiation.

Authors:  M S Wilke; B M Hsu; J J Wille; M R Pittelkow; R E Scott
Journal:  Am J Pathol       Date:  1988-04       Impact factor: 4.307

6.  Aproliferin--a human plasma protein that induces the irreversible loss of proliferative potential associated with terminal differentiation.

Authors:  M L Wier; R E Scott
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

7.  Hormonal regulation of the transformation phenotype in simian virus 40-transformed rat embryonic preadipose cell lines.

Authors:  S Yasumoto
Journal:  Mol Cell Biol       Date:  1984-04       Impact factor: 4.272

8.  The development of adipocytes in primary stromal-vascular culture of fetal pig adipose tissue.

Authors:  G J Hausman; J E Novakofski; R J Martin; G B Thomas
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

9.  An initiator of carcinogenesis selectively and stably inhibits stem cell differentiation: a concept that initiation of carcinogenesis involves multiple phases.

Authors:  R E Scott; P B Maercklein
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

10.  Induction of preadipocyte differentiation by mature fat cells in the rat.

Authors:  G Shillabeer; J M Forden; D C Lau
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.